Connecticut biotech Loxo Oncology is hoping to upend decades of Food and Drug Administration dogma with its cancer drug, seeking what would be a pioneering approval to treat a wide array of tumors with one pill. And, judging from an early peek at Loxo’s clinical data, experts say the plan just might work.

Loxo’s drug, larotrectinib, is designed to kill off tumors by attacking a protein called TRK, which becomes hyperactive in people with certain genetic mutations. But where most drugs are studied in one cancer type at a time, Loxo aims to market its therapy for any tumor that expresses the TRK protein, and it’s building up evidence to convince the FDA.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Ignyta’s product Entrectinib is having good results, works on a variety of tumors that have TRK and other mutations AND passes the blood brain barrier. Disclosure I have a family member in a trial and she has had amazing results and we are very grateful. Your mileage may vary.

  • Isn’t this what just got approved with Merck’s Keytruda (pembrolizumab), based on PD-L1 expression biomarker, not tumor location? Loxo isn’t breaking any new barriers.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy